Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cabozantinib s-malate by Exelixis for Metastatic Breast Cancer: Likelihood of Approval
Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Metastatic Breast Cancer. According to GlobalData,...
Cabozantinib s-malate by Exelixis for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Cabozantinib s-malate by Exelixis for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Recurrent Head And Neck Squamous Cell...
Zanzalintinib fumarate by Exelixis for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Oral Cavity (Mouth) Cancer. According to...
Zanzalintinib fumarate by Exelixis for Oropharyngeal Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase...
Zanzalintinib fumarate by Exelixis for Laryngeal Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Laryngeal Cancer. According to GlobalData, Phase...
Zanzalintinib fumarate by Exelixis for Hypopharyngeal Cancer: Likelihood of Approval
Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase III for Hypopharyngeal Cancer. According to GlobalData, Phase...
Cabozantinib s-malate by Exelixis for Esophageal Cancer: Likelihood of Approval
Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
Cabometyx by Exelixis for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval
Cabometyx is under clinical development by Exelixis and currently in Pre-Registration for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to GlobalData, Pre-Registration...
Cabozantinib s-malate by Exelixis for Penile Cancer: Likelihood of Approval
Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Penile Cancer. According to GlobalData, Phase...
Cabometyx by Exelixis for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Cabometyx is under clinical development by Exelixis and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData,...
Cabometyx by Exelixis for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Cabometyx is under clinical development by Exelixis and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to...
Cabometyx by Exelixis for Gastric Cancer: Likelihood of Approval
Cabometyx is under clinical development by Exelixis and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...
Cabometyx by Exelixis for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval
Cabometyx is under clinical development by Exelixis and currently in Pre-Registration for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to GlobalData, Pre-Registration...
Cabozantinib s-malate by Exelixis for Penile Cancer: Likelihood of Approval
Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Penile Cancer. According to GlobalData, Phase...
XL-888 by Exelixis for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
XL-888 is under clinical development by Exelixis and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas. According to...
XL-888 by Exelixis for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
XL-888 is under clinical development by Exelixis and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According to...
XL-888 by Exelixis for Small Intestine Cancer: Likelihood of Approval
XL-888 is under clinical development by Exelixis and currently in Phase I for Small Intestine Cancer. According to GlobalData, Phase...
XL-888 by Exelixis for Hepatocellular Carcinoma: Likelihood of Approval
XL-888 is under clinical development by Exelixis and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I...
XL-888 by Exelixis for Gastric Cancer: Likelihood of Approval
XL-888 is under clinical development by Exelixis and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...